RA Capital Management UNCY Position
ExitedRA Capital Management exited their position in Unicycive Therapeutics, Inc. (UNCY) in Q1 2024, after holding the stock for 2 quarters.
The position was first reported in Q4 2023 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds UNCY.
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Full company profile →Short Interest
8.0%
3.6 days to cover
RA Capital Management UNCY Position History
Frequently Asked Questions
Does RA Capital Management own UNCY?
No. RA Capital Management exited their position in Unicycive Therapeutics, Inc. (UNCY) in Q1 2024. They previously held the stock for 2 quarters.
How many hedge funds own UNCY?
1 specialist biotech hedge fund currently holds UNCY, including BVF Partners. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy UNCY?
RA Capital Management's position in UNCY was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's UNCY position increasing or decreasing?
RA Capital Management completely exited their UNCY position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
UNCYCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →